Wu G X, Wu J C, Ma H T, Ruan C G
Jiangsu Institute of Hematology, Suzhou Medical College, China.
Zhongguo Yao Li Xue Bao. 1992 Jul;13(4):330-3.
The corrected platelet count at the end of cardiopulmonary bypass (CPB) in nontreated dogs fell to 56.7% of the pre-operative level, while in tetramethylpyrazine (TMP, 10 mg.kg-1, iv)-treated dogs it fell to 82.8%. The number of alpha-granule membrane protein (GMP-140) which was expressed on the surface of activated platelets increased from the outset of CPB and reached the peak at the end of CPB in control dogs. But the number of GMP-140 molecules did not increase significantly throughout the operative procedure in TMP-treated dogs. In experimental thrombosis in dogs, the weight of the thrombus reduced to 23% of that in controls and the radioactivity ratio between the thrombus and blood was only 29% of that in controls at 4 h after iv injection of 125I-SZ-51 (a monoclonal antibody against GMP-140). These results indicate that TMP inhibits the platelet activation during CPB and arterial thrombosis.
在未治疗的犬类中，体外循环（CPB）结束时校正后的血小板计数降至术前水平的56.7%，而在接受川芎嗪（TMP，10mg·kg-1，静脉注射）治疗的犬类中，该计数降至82.8%。活化血小板表面表达的α-颗粒膜蛋白（GMP-140）数量从CPB开始时增加，并在对照犬的CPB结束时达到峰值。但在TMP治疗的犬类中，整个手术过程中GMP-140分子数量没有显著增加。在犬类实验性血栓形成中，静脉注射125I-SZ-51（一种抗GMP-140单克隆抗体）4小时后，血栓重量降至对照组的23%，血栓与血液的放射性比率仅为对照组的29%。这些结果表明，川芎嗪可抑制CPB期间的血小板活化和动脉血栓形成。
